Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 8.

Friis-Møller, Nina; Ryom, Lene; Smith, Colette; Weber, Rainer; Reiss, Peter; Dabis, F; De Wit, Stephane; Monforte, Antonella D'Arminio; Kirk, Ole; Fontas, Eric; Sabin, Caroline; Phillips, Andrew; Lundgren, Jens; Law, Matthew (2016). An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. European Journal of Preventive Cardiology, 23(2):214-223.

Worm, S W; Kamara, D A; Reiss, P; Fontas, E; De Wit, S; El-Sadr, W; D'Arminio Monforte, A; Law, M; Phillips, A; Ryom, L; Dabis, F; Weber, R; Sabin, C; Lundgren, J D (2012). Evaluation of HIV protease inhibitor use and the risk of sudden death or nonhemorrhagic stroke. Journal of Infectious Diseases, 205(4):535-539.

Weber, R; Sabin, C; Reiss, P; De Wit, S; Worm, S W; Law, M; Dabis, F; D'Arminio Monforte, A; Fontas, E; El-Sadr, W; Kirk, O; Rickenbach, M; Phillips, A; Ledergerber, B; Lundgren, J (2010). HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D cohort study. Antiviral Therapy, 15(8):1077-1086.

Worm, S W; Sabin, C; Weber, R; Reiss, P; El-Sadr, W; Dabis, F; De Wit, S; Law, M; D'Arminio Monforte, A; Friis-Møller, N; Kirk, O; Fontas, E; Weller, I; Phillips, A; Lundgren, J (2010). Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. Journal of Infectious Diseases, 201(3):318-330.

Worm, S W; De Wit, S; Weber, R; Sabin, C A; Reiss, P; El-Sadr, W; Monforte, A D; Kirk, O; Fontas, E; Dabis, F; Law, M G; Lundgren, J D; Friis-Møller, N (2009). Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study). Circulation, 119(6):805-811.

Sterne, J A C; May, M; Costagliola, D; de Wolf, F; Phillips, A N; Harris, R; Funk, M J; Geskus, R B; Gill, J; Dabis, F; Miró, J M; Justice, A C; Ledergerber, B; Fätkenheuer, G; Hogg, R S; Monforte, A D; Saag, M; Smith, C; Staszewski, Sc; Egger, M; Cole, S R (2009). Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet, 373(9672):1352-1363.

Mugavero, M J; May, M; Harris, R; Saag, M S; Costagliola, D; Egger, M; Phillips, A; Günthard, H F; Dabis, F; Hogg, R; de Wolf, F; Fatkenheuer, G; Gill, M J; Justice, A; D'Arminio Monforte, A; Lampe, F; Miró, J M; Staszewski, S; Sterne, J A C (2008). Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice? AIDS, 22(18):2481-2492.

Sabin, C A; Worm, S W; Weber, R; Reiss, P; El-Sadr, W; Dabis, F; De Wit, S; Law, M; D'Arminio Monforte, A; Friis-Møller, N; Kirk, O; Pradier, C; Weller, I; Phillips, A N; Lundgren, J D; D:A:D Study Group (2008). Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet, 371(9622):1417-1426.

This list was generated on Fri Nov 17 23:22:46 2017 CET.